Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe.

Détails

ID Serval
serval:BIB_28962
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe.
Périodique
Clinical Microbiology and Infection
Auteur⸱e⸱s
Jones R.N., Pfaller M.A.
ISSN
1198-743X
Statut éditorial
Publié
Date de publication
2003
Volume
9
Numéro
7
Pages
708-712
Langue
anglais
Résumé
Extended-spectrum beta-lactamases (ESBLs) have continued to evolve after their initial detection in Europe nearly two decades ago. The summary results from the MYSTIC Program (31 medical centers) were utilized to assess the extent of ESBL occurrence in Europe from 1997 to 2000. ESBL phenotype rates in Klebsiella spp. (32.8%) and Escherichia coli (14.4%) were generally stable, but extensive hospital-to-hospital and unit-to-unit variations were noted. The highest ESBL rates were found in eastern Europe (including Turkey) and in intensive care unit patient populations. Carbapenems remained active against the ESBL-producing strains (meropenem MIC90, 0.25-1 mg/L), while some other agents, such as aminoglycosides, fluoroquinolones, and piperacillin-tazobactam, were significantly less effective. International surveillance initiatives should be maintained to monitor future progression of this important resistance.
Mots-clé
Anti-Bacterial Agents/pharmacology, Drug Resistance, Bacterial/physiology, Escherichia coli/drug effects, Escherichia coli/enzymology, Europe, Klebsiella/drug effects, Klebsiella/enzymology, beta-Lactamases/metabolism
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/11/2007 13:26
Dernière modification de la notice
20/08/2019 14:08
Données d'usage